1 Min Read
March 28 (Reuters) - MiMedx Group Inc:
* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.